Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352

~ Collaborative efforts are aimed at using Lantern’s AI platform to accelerate and sharpen the drug development of TTC-352. ~ The collaboration will utilize Lantern’s AI-based capabilities and RADR® platform to uncover efficacy-associated biological signatures and biomarkers to advance the clinical development and strategic positioning of TTC Oncology’s leading drug candidate, TTC-352. ~ Phase 2 ready candidate, TTC-352, is a novel, first- and best-in-class selective human estrogen receptor (ER) partial agonist (ShERPA) for the treatment of patients with metastatic ER+ breast cancer. ~ Lantern is receiving exclusive rights to license TTC-352 during an exclusive option period, which includes rights to intellectual property generated during the collaboration.